Updates on BTK Inhibitors and Multiple Sclerosis Trials - Part 1

episode

Neurology Minute not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

A.I. Safety Goes Mainstream + a ‘Hard Fork’ Exit AMA 1h 25m · 18 Sep 2026 · Hard Fork

Layoffs at the Kansas City Star will hurt local communities 15 min · 18 Sep 2026 · Kansas City Today

AWP: Beyond the Exam Room: Purpose, Myopia, and Population Health 54 min · 17 Sep 2026 · EyeCode Media

Planning Commission Meeting - Sep 17, 2026 1h 11m · 17 Sep 2026 · Leesburg Planning Commission

Heritage Commission - Sep 14, 2026 1h 57m · 17 Sep 2026 · Loudoun County Board Committees and Advisory Boards

Historic District Review Committee - Sep 14, 2026 1h 36m · 17 Sep 2026 · Loudoun County Board Committees and Advisory Boards

Report any issue

Source

Recorded30 Jul 2026

Publisherneurologyminute.libsyn.com ↗

Handlerec:19581397

Show notes

In part one of this series, Drs. Shuvro Roy, Jiwon Oh, and Amit Bar-Or discuss the results of the fenebrutinib trial and highlight the key takeaways that healthcare providers should be aware of. For more information, please read about the abstract that was presented at the 2026 AAN Annual Meeting. Read more about the Fenebrutinib Trial.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in